Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Oculo-facial-skeletal myorhythmia in Whipple disease: treatment with ceftriaxone

Article Abstract:

Whipple disease is a chronic disorder that affects the entire body. It results in steatorrhea or fatty stools, weight loss, arthralgia or joint pain, fever, and nerve-related symptoms. Some central nervous system changes include headache, seizures, and meningitis, or inflammation of the membrane lining the brain and spinal cord. Patients with Whipple disease display a movement disorder called oculomasticatory or oculo-facial-skeletal myorhythmia. A case is described of a 43-year-old man with Whipple disease, who developed amnesia, meningitis, eye paralysis, and oculo-facial-skeletal myorhythmia. He improved after penicillin treatment, but suffered a central nervous system relapse. He developed amnesia, recurrent headaches, and myorhythmia. These symptoms resolved after inpatient treatment with the antibiotic ceftriaxone, which was administered intravenously (by IV). When he was discharged home, he continued to take another antibiotic, doxycycline. Nerve-related symptoms in Whipple disease do not commonly respond to therapy, but disease progression can be prevented by antibiotics, such as chloramphenicol, trimethoprim-sulfamethoxazole, tetracycline, and erythromycin. This is the first report of successful treatment of nerve-related symptoms of Whipple disease with the antibiotic ceftriaxone. (Consumer Summary produced by Reliance Medical Information, Inc.)

Author: Adler, Charles H., Galetta, Steven L.
Publisher: American College of Physicians
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 1990
Case studies, Evaluation, Central nervous system diseases, Ceftriaxone, Ceftriaxone sodium

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Detection of a clonal BCL2 gene rearrangement in tissues from a patient with Whipple disease

Article Abstract:

Antibiotic treatment may be effective in patients with Whipple disease who also have genetic evidence for an encapsulated type of lymph cancer called follicular lymphoma. Whipple disease is a rare bacterial infection. Researchers presented the medical history of a 44-year old patient suspected of having a lymphoma in the abdomen. Tissue sample tests indicated that the patient had Whipple disease. Initial tests on the patient's blood, lymph and bone marrow samples showed a gene rearrangement consistent with follicular lymphoma. There was no other evidence of lymphoma in this patient. Symptoms improved and the gene rearrangement was not present 3 and 12 months following treatment with penicillin, tobramycin, and trimethoprim-sulfamethoxazole.

Author: Pron, Benedicte, Fest, Thierry, Lefranc, Marie-Paule, Pierre, Catherine, Angonin, Regis, Wazieres, Benoit de, Soua, Zohra, Dupond, Jean-Louis
Publisher: American College of Physicians
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 1996
Antibiotics, Drug therapy, Genetic aspects, Lymphoma, Giant follicular

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA



Subjects list: Health aspects, Whipple's disease
Similar abstracts:
  • Abstracts: Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine. Secondary osteoporosis: the potential relevance of leptin and low body weight
  • Abstracts: The cellular basis of hepatic fibrosis: mechanisms and treatment strategies. Is liver fibrosis reversible?
  • Abstracts: Placental corticotropin-releasing hormone: function and regulation. Changes in salivary estriol increases before parturition at term
  • Abstracts: HIV-inducing factor in cervicovaginal secretions is associated with bacterial vaginosis in HIV-1-infected women
  • Abstracts: Dietary intake in five ageing cohorts of men in Finland, Italy and the Netherlands. Dietary habits during adolescence - results of the Belgian Adolux Study
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.